

**PRESS RELEASE**

**Heidelberg Pharma Presents Proprietary ATAC Technology Platform at Two Scientific Conferences**

**Ladenburg, Germany, 9 April 2018** – Heidelberg Pharma AG (FSE: WL6) today announced that they will present their proprietary ATAC technology platform at two upcoming scientific conferences.

**6<sup>th</sup> Annual Antibodies & Antibody Drug Conjugates Conference**

Date: 9 – 10 April 2018

Venue: Copthorne Tara Hotel London Kensington, London, UK

Professor Andreas Pahl will present the following speech on Monday, 9 April 2018 at 11.40 a.m. BST:

**Antibody Targeted Amanitin Conjugates (ATACs) - Expanding the ADC landscape with a new payload targeting RNA Polymerase II**

**AACR Annual Meeting 2018**

Date: 14 – 18 April 2018

Venue: McCormick Place North/South, Chicago, USA

Heidelberg Pharma will announce scientific data in the course of two poster presentations. One poster shows structure-effect relationships for synthetic variants of Amanitin-linker molecules which are particularly suitable for the treatment of solid tumors. The other poster shows preclinical data of an ATAC which is directed to PSMA. This protein is relevant inter alia for prostate cancer.

Details of the presentations:

**Structure-Activity relationship of Linker-Amanitin variants and optimization of Linker-Amanitin derivatives for the treatment of solid tumors**

Abstract number: 735, Section 35

Speaker: Dr. Michael Kulke

Date: Sunday, 15 April 2018, 1.00 p.m. – 5.00 p.m. CDT

**Preclinical evaluation of an anti-PSMA antibody-targeted Amanitin conjugate**

Abstract number: 740, Section 35

Speaker: Dr. Christian Breunig

Date: Sunday, 15 April 2018, 1.00 p.m. – 5.00 p.m. CDT

The abstracts of the presentations are available on the website of AACR:

<http://www.abstractsonline.com/pp8/#!/4562/presentation/2997> and

<http://www.abstractsonline.com/pp8/#!/4562/presentation/3002>.

### **About Heidelberg Pharma's proprietary ATAC technology**

Antibody Drug Conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer. Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules. Amatoxins are small bicyclic peptides naturally occurring in the death cap mushroom. They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combating even quiescent tumor cells.

### **About Heidelberg Pharma**

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates. The proprietary lead candidate is HDP-101, a BCMA ATAC for multiple myeloma.

The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON<sup>®</sup> and REDECTANE<sup>®</sup>, while RENCAREX<sup>®</sup> is available for out-licensing and further development. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at [www.heidelberg-pharma.com](http://www.heidelberg-pharma.com).

#### **Contact**

Heidelberg Pharma AG  
Corporate Communications  
Sylvia Wimmer  
Tel.: +49 89 41 31 38-29  
E-Mail: [investors\[at\]hdpharma.com](mailto:investors[at]hdpharma.com)  
Schriesheimer Str. 101, 68526 Ladenburg

#### **IR/PR support**

MC Services AG  
Katja Arnold (CIRO)  
Managing Director & Partner  
Tel.: +49 89 210 228-40  
Mobil: +49 160 9360 3022  
E-Mail: [katja.arnold\[at\]mc-services.eu](mailto:katja.arnold[at]mc-services.eu)

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.